In the Year of the Pig, two new shares rushed to raise a total of 4.1 billion. The stone medicine industry traded 6465 yuan per hand.

In the Year of the Pig, two new shares rushed to raise a total of 4.1 billion. The stone medicine industry traded 6465 yuan per hand.

The first new stocks in the Year of the Pig were released. Cornerstone Pharmaceuticals (02616) and Dickson China (02019) started their dual offerings today, raising a total of 4.115 billion yuan. According to foreign reports, Guizhou Bank plans to list in Hong Kong this year, raising up to 1 billion US dollars (about 7.8 billion Hong Kong dollars).

Keishi Pharmaceutical will offer shares from today to next Tuesday (19th), with an offer price of between 11.1 and 12.8 yuan per share. It plans to sell 186 million shares, 10% of which will be offered for public sale. The fund raising will be up to about 2.386 billion yuan and 500 shares in one lot. Fee 6464.49 yuan, listed on the 26th of this month.

Cornerstone intends to set up its own production line

The company introduced five cornerstone investors, including Indus Funds, Boyu Capital, Yishang Capital, Singapore Sovereign Fund GIC and its Tetrad Ventures, to subscribe for a total of US$95 million (approximately HK$741 million) of shares, accounting for 31.24 of the total capital raised this time. % to 36.03% and a 6-month lock-up period.

Jiang Ningjun, chairman and chief executive officer of Keshi Pharmaceutical, said that the new incidence of tumors in mainland patients is twice that of the United States, and the demand for patients is large. The tumor immunotherapy backbone drugs PD-L1 and PD-1 are in clinical stage, and I hope to launch them as soon as possible. However, he did not disclose the timetable; he also pointed out that although there are many similar new products on the market, but the mainland market is huge, I believe that it can form a healthy competition, the company will continue to develop new drugs and cancer vaccines.

Keishi Pharmaceutical cooperates with WuXi PharmaTech (02359) to handle a large number of pre-clinical work by WuXi PharmaTech. The cornerstone will pay for research and development services. After reaching a number of milestones in the contract, WuXi PharmaTech will transfer the knowledge generated during the R&D process. property.

At present, the drug production of the cornerstone pharmaceutical industry is manufactured by a third-party pharmaceutical company. Jiang Ningjun revealed that it is building a production base of its own, ensuring that once the drug is introduced, it has a backup production line. Cornerstone Pharmaceuticals lost 1.16 billion yuan in the first nine months of last year.

Another real-time offering is Zhejiang Real Estate Developer Dickson China, with an offer price ranging from 2.32 to 3.25 yuan, with 532 million shares sold, 10% of which are on sale, raising a maximum of 1.729 billion yuan, 1,000 shares in one lot, and admission fee of 3282.75 yuan. The offer will be listed on the 26th of this month as of next Tuesday. The company introduced China Construction Investment Trust as a cornerstone investor and subscribed for 51 million yuan of shares.

Asked about this year’s sales target or the overall mainland market view, Dexin China President Fei Zhongmin said that it will expand in the Yangtze River Delta and major cities in the country with a sound attitude.

Guizhou Bank deployed Hong Kong to raise 7.8 billion

In addition, Reuters’ IFR quoted people familiar with the matter, Guizhou Bank plans to go public in Hong Kong, raising up to 1 billion US dollars (about 7.8 billion Hong Kong dollars). Guizhou Bank was established in 2012 and was formed by the merger of three local commercial banks, Zunyi, Anshun and Liupanshui. The bank’s net profit for the first half of last year was 1.4 billion yuan (RMB. The same below), with a revenue of 4.1 billion yuan and total assets of 306 billion yuan during the period.

In addition, Hong Kong’s first “wedding stock” Jiayi Holdings is preparing for a prospectus and will hold a press conference today.